Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of Immune Checkpoint Inhibitors PD-1 Monoclonal Antibody and Radiotherapy for Recurrent, Metastatic and Persistent Advanced Cervical Cancer: A Retrospective Cohort Study

NCT05310305 is registered in ClinicalTrials.gov with Lei Li as lead sponsor.

NCT NCT05310305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05310305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of Immune Checkpoint Inhibitors PD-1 Monoclonal Antibody and Radiotherapy for Recurrent, Metastatic and Persistent Advanced Cervical Cancer: A Retrospective Cohort Study
Lead sponsor
Lei Li
Phase
Observational
Overall status
Unknown status
Start date
March 26, 2022
Completion date
March 26, 2023
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anti-programmed death-1 antibody, immune checkpoint inhibitors, metastatic cervical carcinoma, objective remission rate, overall survival, persistent advanced cervical carcinoma, progression-free survival, radiotherapy, recurrent cervical carcinoma, severe adverse events